Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

LXRX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns positive

Q1 FY2026 net change in cash was $3.76M, compared with -$3.77M a year earlier. Trailing-twelve-month net change in cash was $4.2M. Over 3 fiscal years it compounded at -42.7% a year.

Context

  • Net change in cash amounted to 6.7% of revenue in FY2025, down 135.5 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near $3.76M or moves back toward the trailing-twelve-month quarterly average of $1.05M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.76M+124.5% QoQ
Last fiscal yearDec 2025
-$3.33M-107.5% YoY
LTMMar 2026
$4.2M+112.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+199.9%——
1 year-107.5%——
3-year CAGR-42.7%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(3.33M) USD
Year-over-year change
-107.5%

Net Change in Cash vs competitors

How LXRX compares with its peers on the latest reported figures

  • LXRX's LTM Mar 2026 net change in cash of $4.2M is the 10th largest of the 11 companies compared; the peer median is $3.9M.
  • Its year-over-year change of +112.5% is the 5th highest of 11, against a peer median of +6.5%.
  • Net change in cash amounts to 6.0% of revenue for LXRX, versus a peer median of 3.8%.
LXRX Competitors Peer median
Net Change in Cash for LXRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$72.93M +856.8%-54.9%1024.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$42.04M -1225.2%—4.4%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$33.26M -90.9%+27.2%3.3%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$29.02M -171.1%-14.4%—
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$21.41M -320.3%-20.0%2.3%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$21.32M -205.5%—7.1%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$19M +133.9%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$7.06M +200.5%-55.8%—
MNKDMannKind CorporationLTM Mar 2026$5.53M +103.8%—1.5%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$4.2M +112.5%-42.7%6.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$2.28M +363.2%+743.9%—
Peer median (excluding LXRX) $3.9M+6.5%-17.2%3.8%

Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Depreciation & Amortization292K427K554K534K621K
Deferred Income Tax49K0000
Stock-Based Compensation10.58M11.52M14.34M13.5M12.52M
Change in Working Capital(10.23M)402K2.66M14.24M(26.89M)
Accounts Receivables381K(14K)(982K)(2.46M)1.09M
Inventory00(381K)150K(50K)
Accounts Payables(14.16M)76K6.45M14.8M(30.22M)
Other Working Capital3.55M340K(2.43M)1.75M2.29M
Other Non-Cash Items54K744K(2.33M)(6.65M)(3.75M)
Operating Cash Flow(87.02M)(88.85M)(161.9M)(178.78M)(67.85M)
Capital Expenditures(1.22M)(1.33M)(470K)(1.03M)0
Acquisitions (Net)(3.33M)69.75M000
Purchases of Investments(34.26M)(133.95M)(223.34M)(338.05M)(143.55M)
Sales of Investments37.59M64.2M173.87M314.4M252.86M
Other Investing Activities3.33M(69.75M)09.31M3.71M
Investing Cash Flow2.11M(71.08M)(49.94M)(15.38M)113.02M
Debt Repayment(11.7M)48.87M49.96M0(48M)
Common Stock Issued37.08M94.21M138.82M64K73K
Common Stock Repurchased(2.68M)(864K)(824K)(1.73M)0
Dividends Paid00000
Other Financing Activities094.21M0(1.24M)(572K)
Financing Cash Flow22.71M142.21M187.96M238.35M(48.5M)
Effect of Forex Changes00000
Net Change in Cash(62.2M)(17.72M)(23.88M)44.19M(3.33M)
Free Cash Flow(88.24M)(90.18M)(162.37M)(179.81M)(67.85M)

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.